WebTH3RESA study, published in 2014, showed that trastuzumab emtansine was associated with statistically significant improvements in progression-free survival and a more … Web4 Sep 2024 · All of the patients in the TH3RESA study had received at least two lines of previous treatment, including trastuzumab, lapatinib, or taxanes. In the EMILIA study, the …
Trastuzumab emtansine versus treatment of physician
Web4 Apr 2024 · 此外，对于吡咯替尼治疗后进展的患者而言，考虑到tki和adc药物作用机制不同，二者序贯使用不存在交叉耐药，并且既往t-dm1的th3resa研究，以及t-dxd的destiny-breast01、destiny-breast02等后线治疗研究均纳入tki经治患者，而后续接受adc类药物同样获益明显，提示吡咯替尼序贯adc类药物是一种可行的治疗模式。 Web11 Jul 2024 · The current study indicated that both T-DXd and T-DM1 presented better efficacy than TKIs regarding survival outcomes. Treatments containing neratinib or T-DM1 tended to rank the best in reducing the recurrent rate of CNS. Our study provides more evidence for the clinical decision making for patients with HER2-positive BCBM. ... putin\u0027s new year address
Relationship between tumor biomarkers and efficacy in …
Web28 Sep 2013 · “The TH3RESA study is the second large phase III study in which Kadcyla has improved the amount of time patients with an advanced form of HER2-positive breast … Web14 Apr 2024 · The KATHERINE study (NCT01772472) evaluated adjuvant T-DM1 versus trastuzumab in patients with histologically confirmed, centrally confirmed, HER2-positive, nonmetastatic, invasive primary breast cancer [T1–4, N0–3, M0 (excluding T1aN0 and T1bN0)] at presentation, and residual invasive disease detected pathologically in the … WebThe primary end point is PFS by independent review facility. 48 In the similar TH3RESA study, patients were enrolled in this randomized, two-arm, multicenter, Phase III study evaluating the efficacy and safety of T-DM1 in comparison with the physician’s choice of treatment. 9 The study has completed enrollment, with 604 patients enrolled. Patients in … putin\u0027s official residence